BR0316770A - Formulação farmacêutica, método de produção da mesma e método de tratamento médico - Google Patents

Formulação farmacêutica, método de produção da mesma e método de tratamento médico

Info

Publication number
BR0316770A
BR0316770A BR0316770-4A BR0316770A BR0316770A BR 0316770 A BR0316770 A BR 0316770A BR 0316770 A BR0316770 A BR 0316770A BR 0316770 A BR0316770 A BR 0316770A
Authority
BR
Brazil
Prior art keywords
medical treatment
pharmaceutical formulation
active agents
production method
formulation
Prior art date
Application number
BR0316770-4A
Other languages
English (en)
Inventor
Majid Hameed Abdul Razzak
Ranjith Srilal Gamage
Bantupalli Rao
Original Assignee
Ashmont Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32501630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0316770(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ashmont Holdings Ltd filed Critical Ashmont Holdings Ltd
Publication of BR0316770A publication Critical patent/BR0316770A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"FORMULAçãO FARMACêUTICA, MéTODO DE PRODUçãO DA MESMA E MéTODO DE TRATAMENTO MéDICO". Os métodos da presente invenção e as formulações produzidas a partir desse métodos permitem a integração estável de múltiplos agentes ativos dentro de uma formulação simples. A solubilização de um agente ativo em um solvente apropriado e a adsorção subseq³ente em um meio de sorção confere uma proteção eficaz para a forma ativa contra quaisquer condições adversas dentro do líquido no qual está disperso o meio de sorção carregado com agente ativo. Como uma conseq³ência, o líquido pode ser formulado de modo a preencher os requisitos dos agentes ativos que podem estar incluídos. Como uma conseq³ência, os agentes ativos podem ser estavelmente integrados dentro da formulação.
BR0316770-4A 2002-12-12 2003-12-12 Formulação farmacêutica, método de produção da mesma e método de tratamento médico BR0316770A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ523128A NZ523128A (en) 2002-12-12 2002-12-12 Anthelmintic formulations containing avermectins and or milbemycins
PCT/NZ2003/000272 WO2004052400A1 (en) 2002-12-12 2003-12-12 Pharmaceutical formulation and a method of making same

Publications (1)

Publication Number Publication Date
BR0316770A true BR0316770A (pt) 2005-10-25

Family

ID=32501630

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316770-4A BR0316770A (pt) 2002-12-12 2003-12-12 Formulação farmacêutica, método de produção da mesma e método de tratamento médico

Country Status (10)

Country Link
US (1) US20060198850A1 (pt)
EP (1) EP1581258B1 (pt)
AU (2) AU2003288820B2 (pt)
BR (1) BR0316770A (pt)
DK (1) DK1581258T3 (pt)
HU (1) HUE031069T2 (pt)
NZ (1) NZ523128A (pt)
SI (1) SI1581258T1 (pt)
WO (1) WO2004052400A1 (pt)
ZA (1) ZA200505576B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002952597A0 (en) * 2002-11-11 2002-11-28 Schering-Plough Pty. Limited Topical parasiticide formulations and methods of treatment
PL1836665T3 (pl) 2004-11-19 2013-06-28 Glaxosmithkline Llc Sposób dostosowywania dozowania zmiennych dawek leków w produktach skojarzonych w celu indywidualizowania terapii
AU2010290829A1 (en) * 2009-09-07 2012-04-26 Douglas Robert Cleverly Granulated anthelmintic preparations and delivery systems
WO2011075592A1 (en) 2009-12-17 2011-06-23 Merial Limited Compositions comprising macrocyclic lactone compounds and spirodioxepinoindoles
US20130267590A1 (en) * 2011-09-13 2013-10-10 Dr. Reddy's Laboratories Limited Retigabine compositions
US9770514B2 (en) * 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
ES2696400B2 (es) * 2017-08-03 2019-07-11 Univ Granada Procedimiento de preparacion de un material nanoestructurado de praziquantel y un silicato, material obtenido y uso como antiparasitario

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4607050A (en) * 1981-10-19 1986-08-19 Wellcome Australia Limited Method of controlling insects and parasites with an aqueous localized pour-on formulation
US4678774A (en) * 1985-06-06 1987-07-07 Merck & Co., Inc. Novel synergistic compositions
US4711774A (en) * 1986-03-27 1987-12-08 Warner-Lambert Company Medicament adsorbates with complex magnesium aluminum silicate and their preparation
JPH0585902A (ja) * 1991-09-24 1993-04-06 Nippon Kayaku Co Ltd 生分解性ポリマーを含有する徐放性農薬製剤及びその製造方法
EP0959891A1 (en) * 1996-07-30 1999-12-01 Ashmont Holdings Limited Anthelmintic formulations
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
NZ508969A (en) 1999-06-04 2002-12-20 Nufarm Ltd Pesticidal emulsion containing levamisole in the aqueous phase and a macrocyclic lactone anthelmintic in the organic phase
AU772988B2 (en) * 1999-06-04 2004-05-13 Elanco Tiergesundheit Ag Stable biocidal compositions
US6787342B2 (en) * 2000-02-16 2004-09-07 Merial Limited Paste formulations
AUPQ875700A0 (en) * 2000-07-13 2000-08-03 Reflex Research Limited Combination compositions

Also Published As

Publication number Publication date
EP1581258A1 (en) 2005-10-05
HUE031069T2 (en) 2017-06-28
AU2003288820B2 (en) 2008-08-21
EP1581258B1 (en) 2016-08-31
DK1581258T3 (en) 2016-12-19
ZA200505576B (en) 2006-06-28
AU2008229987A1 (en) 2008-11-06
AU2003288820A1 (en) 2004-06-30
SI1581258T1 (sl) 2018-12-31
WO2004052400A1 (en) 2004-06-24
NZ523128A (en) 2006-01-27
EP1581258A4 (en) 2011-06-15
US20060198850A1 (en) 2006-09-07

Similar Documents

Publication Publication Date Title
Friedman et al. Topical anesthetics update: EMLA and beyond
AR049518A1 (es) Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados
BR0016012A (pt) Implante farmacêutico contendo componentes de liberação imediata e de liberação prolongada, além de processo de administração
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
BRPI0410786A (pt) composição, uso da mesma, e, método de tratamento de um distúrbio de humor em um paciente
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
DK1553927T3 (da) Gel-stabiliserede, nanopartikulære aktivstof-sammensætninger
DE69940015D1 (de) Pharmazeutische zubereitungen enthaltend einen amphoteren emulgator, polyproxylierten cetylalkohol und einen polaren wirkstoff
ECSP034815A (es) "composiciones de timolol y de lipido hipotensivas y los metodos para utilizarlas"
BR0311460A (pt) Composição farmacêutica de liberação modificada, uso de uma formulação, e, método para tratar um distúrbio cardiovascular em um paciente
BR0113247A (pt) Composição, método para o tratamento de desordens da pele em um ser humano, método para o preparo de uma composição
BR0314943A (pt) Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes
BRPI0116945B8 (pt) preparado para tratamento local de epitélio hiperproliferativo
BRPI0819081A8 (pt) Formulação oftálmica aquosa, processo para preparar a mesma, e, método para inibir, tratar ou prevenir doenças oculares e doença ou condição relacionada, em um paciente em necessidade de tal tratamento
BR0309004A (pt) Matriz para liberação gradual, invariante e independente dos compostos ativos
BRPI0408655A (pt) formulações compreendendo um agente ativo e cacau em pó e a sua utilização
BR0109602A (pt) Glóbulos de liberação controlada contendo estavudina
BRPI0413353A (pt) composição farmacêutica contendo droga solúvel em água
BRPI0414320A (pt) composição para tratamento da pele
BR0116251A (pt) composição de lágrimas artificiais contendo uma combinação de três demulcentes
BR9815510A (pt) Sistema terapêutico transdérmico (tts), para a administração transcutânea de esteróides sexuais e método para produção em um tts
US5916574A (en) Method of treating natural poison skin conditions
BR0311414A (pt) Agente terapêutico para uma bexiga hiperativa
BR0210013A (pt) Gel oftálmico de pirenzepina
BR0316770A (pt) Formulação farmacêutica, método de produção da mesma e método de tratamento médico

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: PARA QUE A SOLICITACAO DE DEVOLUCAO DE PRAZO SEJA ANALISADA, A MESMA DEVERA SER APRESENTADA AO INPI ACOMPANHADA DA COPIA DO PEDIDO DE FOTOCOPIA E DOS DEMAIS DOCUMENTOS LEGALMENTE EXIGIVEIS, DE ACORDO COM O ART. 3O DA RESOLUCAO 116/04.

B15Z Prolongation of time limit refused

Free format text: NEGADA A SOLICITACAO DE DEVOLUCAO DE PRAZO POR MOTIVO DE INSUFICIENCIA DE DOCUMENTOS, UMA VEZ QUE A MESMA NAO FOI APRESENTADA AO INPI ACOMPANHADA DA COPIA DO PEDIDO DE FOTOCOPIA E DOS DEMAIS DOCUMENTOS LEGALMENTE EXIGIVEIS, DE ACORDO COM O ART. 3O DA RESOLUCAO 116/04.

B25C Requirement related to requested transfer of rights

Owner name: ASHMONT HOLDINGS LIMITED (NZ)

Free format text: AFIM DE ATENDER A TRANSFERENCIA REQUERIDA ATRAVES DA PETICAO NO 020100075334/RJ DE 13/08/2010, E NECESSARIO REAPRESENTAR O DOCUMENTO DE CESSAO DEVIDAMENTE CONSULARIZADO.

B25A Requested transfer of rights approved

Owner name: MERIAL LIMITED (GB)

Free format text: TRANSFERIDO DE: ASHMONT HOLDINGS LIMITED

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.

B15K Others concerning applications: alteration of classification

Free format text: PROCEDIMENTO AUTOMATICO DE RECLASSIFICACAO. AS CLASSIFICACOES IPC ANTERIORES ERAM: A61K 47/02; A61K 47/04; A61K 47/38; A61K 35/70; A61K 31/365; A61P 33/14; A61P 33/10.

Ipc: A61K 9/00 (2006.01), A61K 9/14 (2006.01), A61K 31/

Ipc: A61K 9/00 (2006.01), A61K 9/14 (2006.01), A61K 31/